Keywords: iBio, Synagis, Palivizumab, AstraZeneca, MedImmune, MAb, RSV

iBio uses iBioLaunch technology to produce functional MAb copy of Synagis

Article | 11 April 2012

Print This

US biotech firm iBio (NYSE AMEX: IBIO) says that its proprietary iBioLaunch technology for the production of biotherapeutic proteins and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in